Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

<p><strong>Objectives</strong> To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis.</p> <p><strong>Methods</strong> Two phase 3, double-blind rand...

Full description

Bibliographic Details
Main Authors: Fleischmann, R, van der Heijde, D, Strand, V, Atsumi, T, McInnes, IB, Takeuchi, T, Taylor, PC, Bracher, M, Brooks, D, Davies, J, Goode, C, Gupta, A, Mukherjee, S, O’Shea, C, Saurigny, D, Schifano, L, Shelton, C, Smith, JE, Wang, M, Wang, R, Watts, S, Weinblatt, M
Format: Journal article
Language:English
Published: BMJ 2023

Similar Items